WO2018095345A1 - 一种7H-吡咯并[2,3-d]嘧啶类化合物的晶型、盐型及其制备方法 - Google Patents
一种7H-吡咯并[2,3-d]嘧啶类化合物的晶型、盐型及其制备方法 Download PDFInfo
- Publication number
- WO2018095345A1 WO2018095345A1 PCT/CN2017/112493 CN2017112493W WO2018095345A1 WO 2018095345 A1 WO2018095345 A1 WO 2018095345A1 CN 2017112493 W CN2017112493 W CN 2017112493W WO 2018095345 A1 WO2018095345 A1 WO 2018095345A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- crystal form
- slightly soluble
- aspects
- ray powder
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
编号 | 溶剂 | 溶解度(mg/mL) | 结论 |
1 | 甲醇 | <2 | 微溶或极微溶解 |
2 | 乙醇 | <2 | 微溶或极微溶解 |
3 | 异丙醇 | <2 | 微溶或极微溶解 |
4 | 正丁醇 | <2 | 微溶或极微溶解 |
5 | 乙腈 | <2 | 微溶或极微溶解 |
6 | 丙酮 | <2 | 微溶或极微溶解 |
7 | 甲基乙基酮 | <2 | 微溶或极微溶解 |
8 | 甲基异丁基酮 | <2 | 微溶或极微溶解 |
9 | 乙酸乙酯 | <2 | 微溶或极微溶解 |
10 | 乙酸异丙酯 | <2 | 微溶或极微溶解 |
11 | 甲基叔丁基醚 | <2 | 微溶或极微溶解 |
12 | 四氢呋喃 | <2 | 微溶或极微溶解 |
13 | 2-甲基四氢呋喃 | <2 | 微溶或极微溶解 |
14 | 甲苯 | <2 | 微溶或极微溶解 |
15 | 庚烷 | <2 | 微溶或极微溶解 |
16 | 环己烷 | <2 | 微溶或极微溶解 |
17 | 1,4-二氧六环 | <2 | 微溶或极微溶解 |
18 | 水 | <2 | 微溶或极微溶解 |
19 | 甲醇-水(1:1) | <2 | 微溶或极微溶解 |
20 | 甲醇-水(3:1) | <2 | 微溶或极微溶解 |
21 | 乙醇-水(1:1) | <2 | 微溶或极微溶解 |
22 | 乙醇-水(3:1) | <2 | 微溶或极微溶解 |
23 | 乙腈-水(1:1) | <2 | 微溶或极微溶解 |
24 | 丙酮-水(1:2) | <2 | 微溶或极微溶解 |
25 | 异丙醇-水(1:1) | <2 | 微溶或极微溶解 |
序号 | 溶剂 | 外观(2天) | 结果 |
1 | 甲醇 | 混悬液 | A晶型 |
2 | 乙醇 | 混悬液 | A晶型 |
3 | 异丙醇 | 混悬液 | A晶型 |
4 | 丙酮 | 混悬液 | A晶型 |
5 | 乙酸乙酯 | 混悬液 | A晶型 |
6 | 四氢呋喃 | 混悬液 | A晶型 |
7 | 甲醇-水(3:1) | 混悬液 | A晶型 |
8 | 乙醇-水(3:1) | 混悬液 | A晶型 |
9 | 丙酮-水(1:2) | 混悬液 | A晶型 |
10 | 异丙醇-水(1:1) | 混悬液 | A晶型 |
化合物 | JAK1 | JAK2 |
化合物1 | A | B |
Claims (20)
- 根据权利要求1所述化合物1的A晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:12.38±0.2°,13.34±0.2°,15.85±0.2°,22.09±0.2°,23.71±0.2°,25.38±0.2°,26.21±0.2°,26.81±0.2°。
- 根据权利要求2所述化合物1的A晶型,其XRPD图谱如图1所示。
- 化合物1的B晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:12.25±0.2°、21.97±0.2°、23.62±0.2°。
- 根据权利要求4所述化合物1的B晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:12.25±0.2°,13.24±0.2°,15.77±0.2°,21.97±0.2°,23.62±0.2°,25.24±0.2°,26.70±0.2°,37.51±0.2°。
- 根据权利要求5所述化合物1的B晶型,其XRPD图谱如图4所示。
- 化合物1的C晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:12.40±0.2°、37.65±0.2°。
- 根据权利要求7所述化合物1的C晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:12.40±0.2°,13.37±0.2°,21.51±0.2°,22.14±0.2°,24.87±0.2°,25.40±0.2°,37.65±0.2°。
- 根据权利要求8所述化合物1的C晶型,其XRPD图谱如图7所示。
- 化合物1的D晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:12.36±0.2°、37.62±0.2°。
- 根据权利要求10所述化合物1的D晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:12.36±0.2°,24.84±0.2°,37.62±0.2°。
- 根据权利要求11所述化合物1的D晶型,其XRPD图谱如图10所示。
- 化合物2的E晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:6.21±0.2°、10.92±0.2°、12.78±0.2°。
- 根据权利要求14所述化合物2的E晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:6.21±0.2°,10.92±0.2°,12.34±0.2°,12.78±0.2°,15.16±0.2°,20.23±0.2°,22.77±0.2°,23.03±0.2°。
- 根据权利要求15所述化合物2的E晶型,其XRPD图谱如图13所示。
- 化合物3的F晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:12.89±0.2°、18.79±0.2°、24.70±0.2°。
- 根据权利要求18所述化合物3的F晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:12.89±0.2°,15.78±0.2°,17.67±0.2°,18.79±0.2°,19.38±0.2°,20.47±0.2°,24.70±0.2°,25.66±0.2°。
- 根据权利要求39所述化合物3的F晶型,其XRPD图谱如图16所示。
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK17873546.0T DK3511333T3 (da) | 2016-11-23 | 2017-11-23 | Krystalform og saltform af 7h-pyrrolo[2,3-d]pyrimidinforbindelse og fremgangsmåde til fremstilling deraf |
EP17873546.0A EP3511333B1 (en) | 2016-11-23 | 2017-11-23 | Crystal form and salt form of 7h-pyrrolo[2,3-d]pyrimidine compound and preparation method therefor |
CN201780045482.4A CN109563097B (zh) | 2016-11-23 | 2017-11-23 | 一种7H-吡咯并[2,3-d]嘧啶类化合物的晶型、盐型及其制备方法 |
MX2019002077A MX2019002077A (es) | 2016-11-23 | 2017-11-23 | Formas cristalinas y formas de sal de compuestos de 7h-pirrolo[2,3-d]pirimidina y metodo de preparacion de las mismas. |
ES17873546T ES2882214T3 (es) | 2016-11-23 | 2017-11-23 | Forma cristalina y forma salina del compuesto 7h-pirrolo[2,3-d]pirimidina y procedimiento de preparación del mismo |
AU2017366375A AU2017366375B2 (en) | 2016-11-23 | 2017-11-23 | Crystal form and salt form of 7H-pyrrolo[2,3-d]pyrimidine compound and preparation method therefor |
EA201990364A EA039655B1 (ru) | 2016-11-23 | 2017-11-23 | КРИСТАЛЛИЧЕСКИЕ И СОЛЕВЫЕ ФОРМЫ 7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
JP2019527838A JP6788114B2 (ja) | 2016-11-23 | 2017-11-23 | 7H−ピロロ[2、3−d]ピリミジン化合物の結晶形、塩型並びにその製造方法 |
US16/336,361 US10774094B2 (en) | 2016-11-23 | 2017-11-23 | Crystal forms and salt forms of 7h-pyrrolo[2,3-d]pyrimidine compounds and preparation method thereof |
CA3033456A CA3033456C (en) | 2016-11-23 | 2017-11-23 | Crystal forms and salt forms of 7h-pyrrolo[2,3-d]pyrimidine compounds and preparation method thereof |
KR1020197006159A KR102136958B1 (ko) | 2016-11-23 | 2017-11-23 | 7H-피롤로[2,3-d]피리미딘 화합물의 결정형, 염형 및 그 제조방법 |
UAA201901913A UA123709C2 (uk) | 2016-11-23 | 2017-11-23 | КРИСТАЛІЧНІ ТА СОЛЬОВІ ФОРМИ 7Н-ПІРОЛО[2,3-d]ПІРИМІДИНІВ І СПОСІБ ЇХ ОДЕРЖАННЯ |
PL17873546T PL3511333T3 (pl) | 2016-11-23 | 2017-11-23 | Postać krystaliczna i forma soli związku 7h-pirolo[2,3-d]pirymidyny oraz sposób ich wytwarzania |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611046683.X | 2016-11-23 | ||
CN201611046683 | 2016-11-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018095345A1 true WO2018095345A1 (zh) | 2018-05-31 |
Family
ID=62195741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/112493 WO2018095345A1 (zh) | 2016-11-23 | 2017-11-23 | 一种7H-吡咯并[2,3-d]嘧啶类化合物的晶型、盐型及其制备方法 |
Country Status (16)
Country | Link |
---|---|
US (1) | US10774094B2 (zh) |
EP (1) | EP3511333B1 (zh) |
JP (1) | JP6788114B2 (zh) |
KR (1) | KR102136958B1 (zh) |
CN (1) | CN109563097B (zh) |
AU (1) | AU2017366375B2 (zh) |
CA (1) | CA3033456C (zh) |
DK (1) | DK3511333T3 (zh) |
EA (1) | EA039655B1 (zh) |
ES (1) | ES2882214T3 (zh) |
HU (1) | HUE055530T2 (zh) |
MX (1) | MX2019002077A (zh) |
PL (1) | PL3511333T3 (zh) |
PT (1) | PT3511333T (zh) |
UA (1) | UA123709C2 (zh) |
WO (1) | WO2018095345A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111039963A (zh) * | 2019-12-31 | 2020-04-21 | 卓和药业集团有限公司 | Wxfl10203614水溶性类似物及其合成方法 |
CN113372366A (zh) * | 2020-12-04 | 2021-09-10 | 广州嘉越医药科技有限公司 | 一种吡咯并嘧啶类化合物的盐、其晶型及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201524977A (zh) * | 2013-12-05 | 2015-07-01 | Pfizer | 吡咯并[2,3-d]嘧啶基、吡咯并[2,3-b]吡基及吡咯并[2,3-d]吡啶基丙烯醯胺 |
CN107531711A (zh) * | 2015-05-29 | 2018-01-02 | 无锡福祈制药有限公司 | Janus激酶抑制剂 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002510687A (ja) * | 1998-04-02 | 2002-04-09 | ニューロゲン コーポレイション | アミノアルキル置換ピロロ[2,3−b]ピリジンおよびピロロ[2,3−d]ピリミジン誘導体:crf1レセプタのモジュレータ |
DK1235830T3 (da) * | 1999-12-10 | 2004-03-29 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer |
GT200200234A (es) * | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
WO2012022045A1 (en) * | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
CA2830463A1 (en) * | 2011-04-08 | 2012-10-11 | Pfizer Inc. | Pharmaceutical composition comprising tofacitinib and a penetration enhancer |
GB201410816D0 (en) * | 2014-06-17 | 2014-07-30 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven | Therapeutic agents |
CN104144337B (zh) | 2014-08-05 | 2016-07-06 | 深圳市华星光电技术有限公司 | 一种多视点立体显示器的图像显示方法及装置 |
CN105367576A (zh) * | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
CN105566327A (zh) * | 2014-10-09 | 2016-05-11 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法 |
-
2017
- 2017-11-23 KR KR1020197006159A patent/KR102136958B1/ko active IP Right Grant
- 2017-11-23 CN CN201780045482.4A patent/CN109563097B/zh active Active
- 2017-11-23 PT PT178735460T patent/PT3511333T/pt unknown
- 2017-11-23 JP JP2019527838A patent/JP6788114B2/ja active Active
- 2017-11-23 AU AU2017366375A patent/AU2017366375B2/en active Active
- 2017-11-23 ES ES17873546T patent/ES2882214T3/es active Active
- 2017-11-23 WO PCT/CN2017/112493 patent/WO2018095345A1/zh unknown
- 2017-11-23 EA EA201990364A patent/EA039655B1/ru unknown
- 2017-11-23 EP EP17873546.0A patent/EP3511333B1/en active Active
- 2017-11-23 CA CA3033456A patent/CA3033456C/en active Active
- 2017-11-23 PL PL17873546T patent/PL3511333T3/pl unknown
- 2017-11-23 HU HUE17873546A patent/HUE055530T2/hu unknown
- 2017-11-23 MX MX2019002077A patent/MX2019002077A/es unknown
- 2017-11-23 US US16/336,361 patent/US10774094B2/en active Active
- 2017-11-23 UA UAA201901913A patent/UA123709C2/uk unknown
- 2017-11-23 DK DK17873546.0T patent/DK3511333T3/da active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201524977A (zh) * | 2013-12-05 | 2015-07-01 | Pfizer | 吡咯并[2,3-d]嘧啶基、吡咯并[2,3-b]吡基及吡咯并[2,3-d]吡啶基丙烯醯胺 |
CN107531711A (zh) * | 2015-05-29 | 2018-01-02 | 无锡福祈制药有限公司 | Janus激酶抑制剂 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111039963A (zh) * | 2019-12-31 | 2020-04-21 | 卓和药业集团有限公司 | Wxfl10203614水溶性类似物及其合成方法 |
CN111039963B (zh) * | 2019-12-31 | 2021-03-19 | 卓和药业集团有限公司 | Wxfl10203614水溶性类似物及其合成方法 |
CN113372366A (zh) * | 2020-12-04 | 2021-09-10 | 广州嘉越医药科技有限公司 | 一种吡咯并嘧啶类化合物的盐、其晶型及其应用 |
CN113372366B (zh) * | 2020-12-04 | 2022-08-30 | 广州嘉越医药科技有限公司 | 一种吡咯并嘧啶类化合物的盐、其晶型及其应用 |
Also Published As
Publication number | Publication date |
---|---|
EP3511333A1 (en) | 2019-07-17 |
US20190218231A1 (en) | 2019-07-18 |
AU2017366375A1 (en) | 2019-04-18 |
KR102136958B1 (ko) | 2020-08-26 |
DK3511333T3 (da) | 2021-08-02 |
ES2882214T3 (es) | 2021-12-01 |
PT3511333T (pt) | 2021-08-02 |
JP2019535771A (ja) | 2019-12-12 |
AU2017366375B2 (en) | 2020-12-03 |
CA3033456A1 (en) | 2018-05-31 |
CA3033456C (en) | 2021-03-09 |
HUE055530T2 (hu) | 2021-12-28 |
KR20190037291A (ko) | 2019-04-05 |
JP6788114B2 (ja) | 2020-11-18 |
EA039655B1 (ru) | 2022-02-22 |
US10774094B2 (en) | 2020-09-15 |
CN109563097A (zh) | 2019-04-02 |
EP3511333A4 (en) | 2019-08-28 |
PL3511333T3 (pl) | 2021-12-06 |
UA123709C2 (uk) | 2021-05-19 |
MX2019002077A (es) | 2019-05-15 |
CN109563097B (zh) | 2021-05-14 |
EA201990364A1 (ru) | 2019-10-31 |
EP3511333B1 (en) | 2021-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9861627B2 (en) | 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1 H-imidazo[4,5-C]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor | |
EP2585465B1 (en) | Benzotriazolodiazepine compounds inhibitors of bromodomains | |
EP2699573B1 (en) | 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1h-imidazo[4,5-c]quinoline derivatives | |
EP2705032B1 (en) | Dihydroquinoline derivatives as bromodomain inhibitors | |
AU2015260905A1 (en) | Pyrazolopyridines and pyrazolopyrimidines | |
MX2012005295A (es) | Inhibidor de bromodominio de benzodiazepina. | |
US20230373974A1 (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
WO2018095345A1 (zh) | 一种7H-吡咯并[2,3-d]嘧啶类化合物的晶型、盐型及其制备方法 | |
WO2017071607A1 (zh) | 4H-吡唑并[1,5-α]苯并咪唑类化合物晶型及其制备方法和中间体 | |
WO2021139794A1 (zh) | 一种吡咯烷基脲衍生物的晶型及其应用 | |
WO2023224924A1 (en) | Solid forms of a macrocyclic compounds as cftr modulators and their preparation | |
CN117645598A (zh) | 氮杂二并多元稠环化合物及其药物组合物和应用 | |
NZ620263B2 (en) | 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17873546 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3033456 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20197006159 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017366375 Country of ref document: AU Date of ref document: 20171123 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017873546 Country of ref document: EP Effective date: 20190411 |
|
ENP | Entry into the national phase |
Ref document number: 2019527838 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |